



JAAS

**Direct analysis of dried blood spots by femtosecond-laser
ablation-inductively coupled plasma-mass spectrometry.
Feasibility of split-flow laser ablation for simultaneous trace
element and isotopic analysis**

Journal:	<i>Journal of Analytical Atomic Spectrometry</i>
Manuscript ID:	JA-ART-09-2014-000313.R1
Article Type:	Paper
Date Submitted by the Author:	05-Nov-2014
Complete List of Authors:	Aramendía, Maite; University of Zaragoza, Rello, Luis; Hospital Miguel Servet, Bérail, Sylvain; Université de Pau et des pays de l'Adour, CNRS, IPREM, LCABIE Donard, Ariane; Université de Pau et des pays de l'Adour, CNRS, IPREM, LCABIE Pecheyran, Christophe; Université de Pau et des pays de l'Adour - CNRS, IPREM, LCABIE Resano, Martin; University of Zaragoza, Department of Analytical Chemistry; University of Zaragoza, Department of Analytical Chemistry

SCHOLARONE™
Manuscripts

1
2
3 **Direct analysis of dried blood spots by femtosecond-laser ablation-**
4 **inductively coupled plasma-mass spectrometry. Feasibility of split-flow**
5 **laser ablation for simultaneous trace element and isotopic analysis**
6
7
8
9

10 M. Aramendía,^{a,b} L. Rello,^c S. Bérail,^d A. Donnard,^d C. Pécheyran,^d M. Resano^{b*}
11

12 ^aCentro Universitario de la Defensa-Academia General Militar de Zaragoza, Carretera de
13 Huesca s/n, 50090, Zaragoza, Spain
14

15 ^bDepartment of Analytical Chemistry, Aragón Institute of Engineering Research (I3A), University
16 of Zaragoza, Pedro Cerbuna 12, 50009 Zaragoza, Spain
17

18 ^cDepartment of Clinical Biochemistry, "Miguel Servet" University Hospital, Paseo Isabel La
19 Católica 1-3, 50009, Zaragoza, Spain
20

21 ^dLCABIE, IPREM UMR 5254, CNRS – Université de Pau et des Pays de l'Adour, 64053, Pau
22 cedex 9, France
23

24 **Abstract**
25

26
27 This work describes a novel procedure based on the use of a 1030 nm
28 femtosecond (fs) laser ablation (LA) device operating at a high repetition rate
29 (30000 Hz) coupled to a sector field-inductively coupled plasma-mass
30 spectrometer (ICP-MS), enabling the complete ablation of dried blood spot
31 (DBS) specimens in a reasonable time (200 s for samples of 5 µL). The
32 integration of the complete signal obtained, in combination with the use of Pt as
33 internal standard (which can be added to the clinical filter paper prior to the
34 blood deposition, ensuring compatibility with unsupervised sample collection
35 schemes), permits obtaining an analytical response that is independent of the
36 particular characteristics of every sample. On the basis of this methodology, an
37 analytical method was developed for the direct determination of several
38 elements (Cd, Co, Cu and Pb) in four blood reference materials as well as in
39 three real samples, providing accurate results in all cases evaluated, at
40 concentration levels ranging from 0.1 to hundreds of µg L⁻¹. Detection limits of
41 0.043 (Cd), 0.42 (Co), 0.54 (Cu), and 0.040 (Pb) µg L⁻¹ are achieved, and
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 precision values most often range between 3 and 9 %RSD.
4
5

6
7 Finally, the potential to couple the LA device simultaneously to a multicollector-
8
9 ICP-MS and a sector field-ICP-MS units by split-flow is also demonstrated, thus
10
11 allowing to obtain both elemental (Co, Cu, Cd and Pb) and isotopic (Cu isotopic
12
13 composition) information from every particular DBS, and therefore maximizing
14
15 the amount of information that can be drawn from a single DBS specimen. Still,
16
17 the precision of the approach is limited at this point, as RSD values of approx.
18
19 1500 ppm and delta variations of almost 4 ‰ were observed for five DBS
20
21 specimens created from the same blood sample.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

In 1963, capillary blood dried on a filter paper (FP) was introduced as a clinical specimen in the U.K. to screen for phenylketonuria in newborns.¹ Since that moment, large scale neonatal screening programs based on the use of dried blood spots (DBS) have been implemented throughout the world, testing for more than thirty disorders and contributing to save and improve many lives.²

In the last few years, the importance of DBS related research has been growing exponentially with more than 1200 articles published since 2010.² At present, a large amount of biomarkers are detected in DBS, not only for screening for metabolic diseases in newborns,³ but also for other purposes such as therapeutic drug monitoring,⁴ pharmacokinetics,⁵ or toxicological^{6,7} and forensic studies.⁶

The reason for this wide acceptance of DBS sampling is certainly related to its inherent advantages in different aspects, which have recently awakened the interest of the pharmaceutical sector in this methodology, thus contributing to its growing success.^{8,9} In this regard, minimally invasive collection of capillary blood *via* finger or heel stick is probably the most important advantage, especially when applied to children under 2 years of age, for whom collection of venous blood is much more traumatic. Additionally, the simplicity of the process for preparing DBS specimens allows for non-specialized personal to carry out this procedure, even in unsupervised contexts such as at the patients' homes. The low amount of sample required to prepare a DBS is also advantageous in other situations such as discovery stage pharmacokinetics, where the use of DBS enables the pharmaceutical companies to better comply with the 3R's (Reduce, Refine, Replace) doctrine with respect to animal experiments

1
2
3 (particularly when small rodents are deployed), allowing for serial sampling from
4
5 a single individual.¹⁰
6
7

8 As a second main advantage, the ease for transport and conservation of
9
10 DBS is also remarkable. Due to the diversity of analytes that can be targeted in
11
12 blood samples, no general conclusions can be drawn about stability of the DBS
13
14 specimens with time and/or storage conditions, as those might depend on the
15
16 particular analyte considered. However, several studies indicate that the filter
17
18 paper has a stabilizing effect on the sample,¹¹ such that DBS specimens do not
19
20 normally require very stringent measures for conservation and/or transport such
21
22 as liquid samples do (i.e. deep freezing at -20°C to -80°C). In fact, conservation
23
24 at room temperature and for large periods of time is possible for many analytes
25
26 including trace elements,^{12,13} so that DBS delivery can be carried out even by
27
28 regular mail.
29
30
31
32
33

34 These features have obvious economical and practical implications. For
35
36 instance, the ease for sample collection and the low cost for preservation and
37
38 delivery can be particularly important for bringing mass screening studies to
39
40 developing countries or remote locations, or for improving results of
41
42 epidemiological studies for which the number of volunteers is low, as
43
44 participants could donate samples without the need to go to the clinic.¹²
45
46 Moreover, the stability of DBS and the low storage requirements make the use
47
48 of these specimens much better suited for biobanking¹⁴ than liquid samples. In
49
50 conclusion, it seems clear from all of the above that extending the use of DBS
51
52 sampling and analysis to as many analytes as possible would be of great
53
54 interest from an economical, ethical, logistical and scientific point of view.
55
56
57
58
59
60

1
2
3 However, and in spite of these advantages, detractors of DBS sampling often
4 cite the relative complexity added to the analytical process, as compared to
5 collection and analysis of venous blood, as a major disadvantage for extending
6 the use of this methodology.¹⁵ In this regard two issues potentially problematic
7 are normally highlighted: (i) difficulties for sample deposition and DBS
8 formation, and (ii) the fact that a liquid sample is converted into a solid one, a
9 *priori*, more difficult to analyze.

10
11 Although potentially problematic, sample deposition for DBS preparation is
12 well established in the clinical practice as described in detail in specialized
13 documents from the UK National Health System¹⁶ or the US Clinical and
14 Laboratory Standards Institute.¹⁷ When quantitative results are needed, the use
15 of US Food and Drug Administration (FDA) approved papers,¹⁸ with a constant
16 sample retention per surface unit, is normally relied upon, although deposition
17 of controlled volumes by using calibrated capillary pipettes is also accepted.⁹
18 More problematic is the influence that variable hematocrit contents, which
19 directly influences sample viscosity, has on blood diffusion and formation of the
20 DBS. Hematocrit is the portion of blood volume occupied by red cells and varies
21 considerably for different individuals.¹⁹ The situation becomes especially
22 problematic when commercial blood reference materials are compared with real
23 samples. In this regard, Czidziel showed, by using Scanning Electron
24 Microscopy, that red cells were absent in DBS prepared from such a reference
25 sample.¹³ As a result, diffusion properties of this material were totally different
26 from those of real samples, which hampered its use for validation or calibration
27 purposes when Pb determination in DBS by means of laser ablation-inductively
28 coupled plasma-mass spectrometry (LA-ICP-MS) was considered.

1
2
3 Development of analytical methods overcoming this difference is therefore
4 highly desirable in the context of DBS quantitative analysis.
5
6

7
8 As for the second problematic issue, i.e. the fact that a DBS is actually a
9 solid sample, this might indeed introduce additional problems if conventional
10 analysis in solution is to be carried out. In these cases, an additional step for
11 extracting the analyte out of the DBS is normally needed, which reduces
12 sample throughput and increases contamination risks.¹⁵ However, and
13 particularly in some areas of application such as trace elemental analysis, direct
14 solid sampling techniques exist that allow for accurate and precise results to be
15 obtained with none or minimal additional sample preparation. This is the case of
16 LA-ICP-MS, a technique providing multielemental trace and ultra-trace as well
17 as isotopic information, which use in all kinds of applications,²⁰⁻²² including
18 bioanalysis,²³⁻²⁸ has increased dramatically in the last few years. However, and
19 in spite of its potential interest, there are few papers in the literature attempting
20 the use of LA-ICP-MS for direct (multi)elemental analysis of DBS,^{13,29,30} and
21 none of them has been fully successful due to different reasons, as will be
22 discussed in detail in section 3.1.1.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 It is the purpose of this paper to develop a methodology for the direct
44 multielemental analysis of DBS at trace and ultra-trace levels by means of LA-
45 ICP-MS, trying to overcome the problem of differential responses for real
46 samples and reference materials, and following as much as possible the
47 recommendations for DBS collection common in the clinical practice as
48 indicated, e.g., by the European Bioanalysis Forum.⁹ Four analytes covering a
49 wide range of masses, Cd, Co, Cu and Pb, were selected for proving the
50 concept. Determination of these analytes is interesting in the clinical setting for
51
52
53
54
55
56
57
58
59
60

1
2
3 different reasons, such as monitoring prosthesis degradation in implanted
4 patients (Co),³¹ revealing exposure to toxic metals (Cd and Pb)⁶ or because the
5 element targeted play a major role in a given medical condition (Cu in the case
6 of Wilson's Disease).³² On the other hand, and considering recent advances in
7 the field of isotopic analysis in biological samples that demonstrate the potential
8 interest of such isotopic information for diagnosis of metal-related diseases,
9 such as Cu isotopes and Wilson's disease,^{33,34} simultaneous determination of
10 Cu isotope ratios with high precision by split-flow coupling of the LA system to a
11 multicollector (MC)-ICP-MS was also attempted.
12
13
14
15
16
17
18
19
20
21
22
23

24 **2. Experimental**

25 **2.1. Chemicals and reagents**

26
27
28
29 All multielement and single element solutions used for preparation of matrix-
30 matched calibration standards and preparation of the Pt internal standard
31 solution were prepared by serial dilution of 1 g L⁻¹ mono elemental standards for
32 ICP-MS (Inorganic Ventures, Christiansburg, USA) with diluted nitric acid until a
33 final concentration of 0.14 M HNO₃. Pro-analysis nitric acid was purchased from
34 Merck (Darmstadt, Germany). Ultrapure water with a resistivity ≥18.2 mΩ·cm
35 was obtained from a Milli-Q system (Millipore, Île-de-France, France).
36
37
38
39
40
41
42
43
44

45
46 Whatman no. 903 paper cards (lot W-092) were obtained from Whatman
47 International Ltd. (Maidstone, U.K.). This is one of the two commercial paper
48 sources registered by the FDA as Class II medical devices.¹⁸ 4.5 cm diameter
49 discs fitting in the LA cell were manually cut out of totally empty cards (non
50 inked) using ceramic scissors.
51
52
53
54
55
56

57 **2.2. Samples and standards**

1
2
3 Four blood reference samples with certified values for the elements targeted
4 in this study were analyzed for validation purposes. Clincheck Whole Blood
5 Control level II was obtained from Recipe Chemicals + Instruments GmbH
6 (Munich, Germany). Seronorm Trace Element Human Whole Blood, level II was
7 obtained from Sero (Billingstad, Norway). Lyphocheck Whole Blood Control,
8 level 1 and level 2 were obtained from BioRad (Hercules, USA). All of these
9 samples are provided as a lyophilized material and were reconstituted in
10 purified water.
11
12
13
14
15
16
17
18
19
20
21

22 Real venous-blood samples from four healthy volunteers were obtained from
23 the Hospital Universitario Miguel Servet (Zaragoza, Spain). Three blood
24 samples were characterized for their trace elemental composition either *via*
25 pneumatic nebulization (PN)-ICP-MS, after 20-fold sample dilution with 0.14 M
26 HNO₃ (Cd and Co), or by means of high-resolution continuum source graphite
27 furnace atomic absorption spectrometry (HR CS GFAAS), after 10-fold sample
28 dilution with 0.14 M HNO₃ (Pb and Cu). Although precipitation of blood proteins
29 was not evident to the bare eye after acid dilution of the samples, proper
30 sample homogeneization was ensured before analysis in order to avoid biased
31 results caused by potential precipitates. For analysis by means of PN-ICP-MS,
32 on the other hand, larger rinsing times between samples were allowed to
33 prevent nebulizer clogging. In all cases external calibration with aqueous
34 standards was used for analysis, with In added as internal reference in the case
35 of PN-ICP-MS.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 Another real sample, which was also analyzed as described above, was
55 used for preparation of matrix-matched calibration standards. For this purpose,
56 1 mL aliquots were spiked with small amounts of multielement solutions
57
58
59
60

1
2
3 prepared in 0.14 M HNO₃ as to obtain a concentration range of spiked amounts
4 ranging from 1 to 2000 µg L⁻¹, depending on the element. The same dilution
5 factor (lower than 2%) was introduced in all cases. The standards prepared in
6 this way were kept for 24h in an automated orbital shaker before deposition on
7 the clinical filter papers was carried out.

8
9
10 Filter paper discs for LA-ICP-MS analysis were prepared following two
11 different procedures, depending on the way the internal standard used as
12 reference (Pt) was added to the DBS specimens. In a first protocol, Pt was
13 directly spiked into the liquid samples, standards and controls until a final Pt
14 concentration of 100 µg L⁻¹. For this purpose, Pt was added to the matrix-
15 matched standards in a multielement solution together with the rest of spiked
16 elements as described above. The same protocol was used for spiking the
17 samples and controls but with a monoelemental Pt solution. Afterwards, 5 or 15
18 µL aliquots of the spiked standards, samples and controls were carefully
19 deposited onto the surface of the filter paper discs, trying to fit as many blood
20 spots as possible on each disc while ensuring enough blank space among them
21 (see **Figure 1** for details). Samples were left to dry at room temperature for at
22 least 4h and, once dried, were kept in sealed plastic bags at room temperature
23 until analysis.

24
25
26 In a second protocol,³⁵ the filter paper discs used for sample deposition were
27 impregnated with a 100 µg L⁻¹ Pt solution and were left to dry at room
28 temperature for at least 4h before deposition of blood was carried out. Once
29 dried, 5 or 15 µL aliquots of matrix-matched standards, samples and controls
30 (non-spiked with Pt) were deposited onto their surface following the same
31 procedure described above. Samples were left to dry at room temperature for at
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 least 4h and, once dried, were kept in sealed plastic bags at room temperature
4
5 until analysis.
6

7 **2.3 Instrumentation and experimental setup for split-flow LA** 8 **measurements** 9

10
11
12 All measurements were carried out using a Lambda 3 femtosecond laser
13 ablation system (Nexeya SA, Canejan, France). This laser is fitted with a diode-
14 pumped Yb:KGW crystal laser source (HP2, Ampitudes Systèmes, Pessac,
15 France) delivering 400 fs pulses. Three wavelengths can be selected: 1030 nm
16 (fundamental), 515 nm (2nd harmonic) and 257 nm (4th harmonic). The 1030 nm
17 wavelength was used in this study. The laser source operates within a wide
18 range of repetition rate (up to 100 kHz) and energy (<2 mJ per pulse below 1
19 kHz and <80 µJ per pulse at 100 kHz at this wavelength), which represents a
20 different approach in analytical applications where high energy and low
21 repetition rate are commonly used. The laser beam is focused with a 100 mm
22 objective, and it can be rapidly moved (up to 2 m s⁻¹) with high repositioning
23 precision thanks to a 2D galvanometric scanning module fitted to the optical
24 line. Further details for a previous and similar model (operating in the IR region
25 only) of this laser ablation system are described elsewhere.^{36,37}
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45
46 Splitting of the carrier gas flow through the LA system has been previously
47 used for simultaneous isotopic and elemental analysis using two ICP-MS
48 systems,³⁸ and this possibility was also tested in the present work. Cu isotopic
49 analysis was carried out on a Nu Plasma HR-MC-ICP-MS instrument (Nu
50 instruments, Wrexham, UK), while multielemental analysis was carried out on
51 an Element XR sector field (SF) ICP-MS instrument (Thermo Scientific,
52 Germany) fitted with a Jet Interface for improved sensitivity. This Jet interface
53
54
55
56
57
58
59
60

1
2
3 consists of a high capacity dry interface pump and a specially designed set of
4
5 cones. Additionally, N₂ has to be added to the dry LA aerosol before entering
6
7 the ICP-MS. A N₂ flow of 10 mL min⁻¹ was added in all the experiments carried
8
9 out in this work. The LA coupling to the two ICP-MS systems was implemented
10
11 using two 10 m long antistatic tubes (PTFE electroconductive, Fisher Bioblock,
12
13 Illkirch Cedex, France) of 6 mm external diameter and 4 mm internal diameter
14
15 into the ICP torches of both instruments, using He as the carrier gas. The He
16
17 carrier gas flow was split after the LA sample cell with a Y-piece. To adjust
18
19 sensitivity, 80% of the He flow was directed to the MC-ICP-MS while the
20
21 remaining 20% was sent to the SF-ICP-MS. Considering the high amount of
22
23 sample ablated and transported to the instruments per second, especially to the
24
25 MC-ICP-MS, a glass fiber filter (37 mm diameter Millipore cassette partially filled
26
27 with chromatographic grade glass wool) was placed before the entrance to the
28
29 ICP torch of this instrument to prevent clogging of the injector tube. A schematic
30
31 drawing of this experimental setup is shown in **Figure 2**.

32
33
34
35
36
37
38 For isotope ratio measurements with the Nu instrument, a two-inlet torch was
39
40 used to mix the laser-generated aerosol together with a liquid aerosol
41
42 (nebulized by means of a pneumatic 200 μL min⁻¹ micro-concentric nebulizer
43
44 combined with a mini-cyclonic Cinnabar spray chamber) before introduction into
45
46 the plasma.^{39,40} This dual-flow introduction system enables easy optimization of
47
48 the MC-ICP-MS by nebulizing a suitable solution for tuning. Furthermore, during
49
50 laser ablation analyses, the plasma was kept under wet conditions by the
51
52 continuous nebulization of a Ni standard solution (1 mg L⁻¹ in 0.14 M HNO₃),
53
54 which was used to correct for mass bias on Cu.
55
56
57
58
59
60

1
2
3 Measuring conditions on the three instruments, summarized in **Table 1**, were
4 adjusted for maximum sensitivity, stability and plasma robustness while
5
6 minimizing the influence of interferences on the analyte signals.
7
8

9
10 A high-resolution continuum source graphite furnace atomic absorption
11 spectrometer ContrAA 700 from Analytik Jena (Jena, Germany) and a
12
13 quadrupole-ICP-MS device (Nexion 300x, Perkin Elmer, Waltham, USA) were
14
15 used for validation purposes when required. A Sartorius (Goettingen, Germany)
16
17 model BP211D analytical balance with a precision of 10^{-5} g was used for
18
19 weighing.
20
21
22
23

24 **2.4 Procedure for simultaneous multielemental and Cu isotope ratio** 25 **analysis of the samples as DBS by means of split flow LA-ICP-MS** 26 27

28
29 The instrumental parameters used for the analysis of the samples are
30 summarized in **Table 1**. The filter paper discs containing the DBS specimens
31
32 were mounted onto plastic holders with the form of an empty cylinder for
33
34 introduction into the LA cell. For avoiding contamination issues, only the rim of
35
36 the disc was in contact with the holder, so that complete ablation of the DBS
37
38 specimens could be carried out without co-ablating the plastic. Each 5 μ L DBS
39
40 was completely ablated by a series of 250-285 concentric circumferences
41
42 (depending on its size), ablated from the inside to the outside of the blood spot
43
44 (see **Figure 3**). For every replicate measurement a transient signal of 200-260
45
46 seconds duration was obtained. For quantitative analysis with the Element XR
47
48 SF-ICP-MS instrument, integration of this transient signal was carried out for
49
50 quantification purposes as described in detail in section 3.1.2. For Cu isotopic
51
52 analysis with the Nu MC-ICP-MS, on the other hand, a linear regression slope
53
54 (LRS) method was used, where the signal intensities for ^{65}Cu were plotted
55
56
57
58
59
60

1
2
3 against the signal intensities for ^{63}Cu . The slope of the regression curve
4
5 provides the raw $^{65}\text{Cu}/^{63}\text{Cu}$ ratio, which is later corrected for mass bias applying
6
7 Russell's exponential law⁴¹ and the signal obtained for a Ni solution that was
8
9 simultaneously nebulized and admixed with the ablated aerosol for this
10
11 purpose. More details on this procedure are provided elsewhere.^{42,43}
12
13
14

15 **3. Results and discussion**

16 **3.1. Quantitative multielemental analysis**

17 *3.1.1. Sample deposition on the filter paper and conditions for ablation of the* 18 19 *DBS specimens* 20 21 22 23

24 As discussed in the introduction, one of the main challenges faced when
25 performing quantitative analyses of biological fluids dried on filter paper, such
26 as DBS, is the occurrence of chromatographic effects both transversally and in-
27 depth, that might affect samples from different patients, standards and/or
28 reference materials in a different way.¹³ The problem becomes especially
29 significant when only a small part of the DBS is sampled, as is the case when
30 conventional LA systems are used, because different results would be obtained
31 depending on the sampling area selected. This problem is probably the reason
32 why there are no works published where quantitative elemental analysis of DBS
33 specimens deposited on FDA approved filter paper cards has been successfully
34 carried out by means of LA-ICP-MS.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 To the best of the authors' knowledge, only three papers have been
51 published attempting this challenge. The first of them explored the technique's
52 possibilities and limitations, studying different DBS specimens prepared with
53 real and reference samples. However, no attempt whatsoever to obtain
54 quantitative information was carried out.¹³
55
56
57
58
59
60

1
2
3 On another paper by Hsieh *et al.*,²⁹ Pb could be quantified (in a reference
4 sample) by means of conventional LA-ICP-MS in very small (0.5 μ L) dried blood
5 spots deposited onto the surface of a hydrophobic (PTFE) filter membrane, and
6 using aqueous standards for calibration. Using this sample deposition, complete
7 desorption of the dried blood/standard droplets could be accomplished by
8 programming a grid of 4 x 5 spots covering the surface of the droplet and using
9 special ablation conditions: 2 mm laser defocus distance, maximum laser
10 energy available, 20 Hz repetition rate and 8 s dwell time on each ablation spot.
11 On a second paper by the same authors³⁰ the same methodology was used to
12 successfully quantify 8 additional elements in reference samples. For Cd
13 determination, however, significant matrix effects were observed and matrix-
14 matched calibration (obtained by serial dilution of a reference material) had to
15 be deployed.

16 Although the method proposed by Hsieh *et al.* permitted to overcome
17 potential chromatographic effects on the DBS by complete desorption of the
18 sample and yielded good analytical results for the quantification of most of the
19 target analytes, blood collection on PTFE slides instead of on FDA approved
20 filter paper cards can be hardly considered as an ideal method for maintaining
21 sample integrity over time and/or through delivery by regular mail, as the
22 sample is not embedded in the PTFE membrane but only sticks to its surface.
23 Moreover, accurate deposition of such small (0.5 μ L) sample volumes (needed
24 for ensuring sample stability as well as minimal matrix effects and for
25 maintaining short drying times) onto such a membrane does not seem
26 straightforward and would probably imply collection of a small quantity of
27 venous blood and sample deposition with a micropipette, which eliminates one
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of the main advantages of the DBS methodology. In any case, and even though
4 the method by Hsieh might not be the most suited for routine analysis due to
5 the potential difficulties discussed above, the idea of ablating the whole DBS for
6 overcoming chromatographic effects and accurately quantifying the analytes
7 irrespectively of the sample origin (reference material or real blood samples) is
8 worth exploring with specimens deposited on FDA-approved filter papers and
9 following as much as possible the usual recommendations for bioanalysis in the
10 clinical practice.⁹ While this possibility seems overly difficult with conventional
11 LA systems delivering high energy laser pulses but at very low repetition rates
12 (up to 20-50 Hz), the use of the Lambda 3 laser, delivering lower energy laser
13 pulses at very high repetition rates (up to 100 KHz), would potentially allow for
14 this ablation strategy.³⁴

15
16 For carrying out this test, deposition of relatively small DBS specimens was
17 considered advantageous for keeping the ablation time to a manageable level,
18 taking into account that the full paper depth should be pierced for avoiding any
19 in-depth variations to affect the final quantification. As a result, deposition of
20 5 μ L blood spots, eventually allowing complete ablation of the DBS in a
21 reasonable time (about 200 s as described below), was considered best for
22 initial optimization of the analytical method.

23
24 As could be anticipated from the results published in the literature,¹³
25 transversal chromatographic effects were visually detectable for the different
26 types of samples under study. As appreciated in **Figure 1**, DBS specimens of
27 similar volume from reconstituted reference blood samples expand over a
28 considerable larger area than those from real blood samples, with some of them
29 even presenting two clearly differentiated areas with different colors. In that
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 situation, complete ablation of the DBS specimen seems totally justified for
4
5 obtaining comparable quantitative results for both the samples and the
6
7 reference materials, one of the main goals of the work. For total ablation of the
8
9 DBS, a series of contiguous concentric circles ablated from the inside to the
10
11 outside of the blood spot was programmed (see **Figure 3**), always ablating a
12
13 small part of the blank paper surrounding the DBS for ensuring complete
14
15 introduction of the blood sample into the ICP. Depending on the DBS size,
16
17 different for CRMs and real samples as seen from **Figure 1**, 250-285 concentric
18
19 circles were needed for complete sample ablation, thus providing transient
20
21 signals of 200-260 seconds duration for the 5 μL DBS specimens. In all cases,
22
23 the complete sample was ablated with the same sampling speed.
24
25
26
27
28

29 *3.1.2. Data treatment and influence of blood volume for DBS preparation*

30
31 As could be expected from the different consistency and dispersion
32
33 properties observed for the different samples and reference materials (**Figure**
34
35 **1**), analysis of the transient signals obtained also revealed different analyte
36
37 distributions along the surface of the DBS for the different specimens, which
38
39 could be also different among the different target elements considered. This
40
41 effect is illustrated for Pb in **Figure 4**. For constructing this figure, the whole
42
43 transient $^{208}\text{Pb}^+$ signals acquired for 5 μL DBS obtained from the reference and
44
45 real samples were divided into slots of 10 seconds duration. Next, the $^{208}\text{Pb}^+$
46
47 signal intensity was integrated for these intervals and the results were
48
49 normalized according to the Pb concentration in the samples, which values
50
51 were available either from the certificate of analysis or from validation analysis
52
53 carried out by means of GFAAS, as described in section 2.2. Taking into
54
55 account the speed of the laser translation movement, each 10 s interval was
56
57
58
59
60

1
2
3 then assigned to its corresponding ablated corona. Results were depicted in the
4 form of a bar graph, each bar representing the normalized area for an ablated
5 corona, whose inner and outer radiuses are displayed in the x-axis. This graph
6 thus represents an approximated radial distribution of Pb in the different DBS
7 analyzed, normalized to a Pb concentration of $1 \mu\text{g L}^{-1}$ for facilitating
8 comparison among the different specimens. The situation depicted in **Figures**
9 **4A** and **4B** represents the typical behavior observed for real samples and
10 CRMs, respectively. The distribution pattern for Pb is similar in both cases, with
11 Pb accumulation at the rim of the DBS. The analyte, however, migrates with the
12 blood droplet, so that individual areas for each corona are lower on average for
13 the reference materials but expand over a larger paper surface. In some
14 extreme cases such as that depicted in **Figure 4C** (that corresponds to one of
15 the reference samples for which two clearly distinct areas could be visually
16 detected in **Figure 1**), Pb distribution was totally different with accumulation at
17 the center of the DBS. In spite of these facts, it is clear from the final results
18 shown in these figures that, although the analyte distribution along the DBS
19 might vary and the consistency might be totally different for samples and
20 reference materials, the total normalized integrated signal for the different DBS
21 specimens remains practically constant. Similar graphs were constructed for the
22 rest of the analytes under study and similar conclusions were reached for all of
23 them. As a result, and in principle, quantification should be possible for DBS
24 analyses provided that total signal integration is performed.

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
At this point, the possibility for using blood volumes greater than $5 \mu\text{L}$ was
considered. In fact, although venous-blood samples were used in this work for
optimization of the analytical method, sample volumes that could be easily

1
2
3 picked in a finger or heel prick by using calibrated capillary pipettes should be
4
5 deployed for the method to fully exploit the advantages of DBS sampling, thus
6
7 having the chance of being implemented in the clinical practice. In this regard, it
8
9 is interesting to highlight that there are commercially available calibrated
10
11 pipettes accurately picking and delivering small sample volumes starting from 5
12
13 $\mu\text{L} \pm 0.3\%$,⁴⁴ thus making the proposed methodology suited for practical
14
15 implementation with capillary blood collection. However, and considering the
16
17 general practice in the clinical setting for neonatal screening studies, where
18
19 larger volumes of capillary blood (up to 50 μL -75 μL) are normally collected, the
20
21 possibility for using the same working strategy for larger DBS specimens was
22
23 considered to be an interesting point for research.
24
25
26
27
28

29 For testing this possibility, 15 μL DBS specimens were prepared from one
30
31 real sample, following the same protocol deployed for 5 μL DBS and detailed in
32
33 section 2.2. The total ablation of these 15 μL DBS needed 365 concentric
34
35 circles, providing transient signals of 430 seconds duration. Integration of the
36
37 signals thus obtained was carried out in a similar way as described before, and
38
39 results were compared to those obtained with 5 μL DBS of the same sample for
40
41 all of the analytes. Comparison of these results is summarized in **Table 2**. As
42
43 seen from this table, the average signal values obtained for 15 μL DBS
44
45 specimens correspond to roughly three times those observed for 5 μL DBS,
46
47 with deviations in the range of 10-15% that were improved down to less than
48
49 10% if internal standard standardization is carried out, as will be described in
50
51 detail in section 3.1.3. This proves that good results can be obtained with the
52
53 working methodology proposed irrespective of the blood volume deployed for
54
55 depositing the DBS.
56
57
58
59
60

3.1.3. Calibration strategy

Taking into account our previous experience with dried urine spots (DUS) analysis,²⁶ calibration with matrix-matched standards was considered in the first place, as heavy matrix effects were expected for this kind of sample if aqueous standards were deployed, particularly considering the large amount of sample ablated per second (about 25 ng s⁻¹ of blood and 18 µg s⁻¹ of filter paper). This possibility is not difficult to implement in this particular case as it is relatively easy for a clinical lab to obtain pooled venous blood samples from healthy patients with low levels of the target analytes and spike them with appropriate concentrations of these elements, or else to acquire commercially available reference blood standards (a feasible possibility as the method developed ensures the same response for real and reference samples). Preparation of these matrix-matched calibration standards is described in section 2.2.

At this point, addition and use of an adequate internal standard (IS) was evaluated. Use of an IS is highly recommended when working with LA-ICP-MS for quantitative purposes for correcting for different ablation efficiencies or sensitivity drifts.²⁴ For this purpose, an element present in all samples and standards for which concentration is constant or known in advance needs to be used. In this regard, and considering the good results obtained in our previous work with DUS,²⁶ addition of a constant Pt amount to all samples and calibration standards was contemplated. This element was considered ideal also in this case, as it is not typically found in blood samples, and should not be affected by spectral overlaps when monitored in a blood matrix by means of ICP-MS. The challenge at this point is to find a way for spiking samples and standards with

1
2
3 the IS but without compromising the inherent advantages of DBS sample
4 collection.
5
6

7
8 Three different approaches for IS application on DBS have been described in
9 the literature for analysis of biomolecules, as detailed in the work by Abu Rabie
10 and coworkers:⁴⁵ (i) direct application of the IS onto the DBS; (ii) addition of the
11 IS to the blood matrix before spotting it onto the paper; and (iii) use of paper
12 discs that were previously pretreated with IS. These options were thus
13 evaluated in the context of the current work. Option (i) was not considered
14 feasible with the means available at our lab. In the work by Abu Rabie, a very
15 fine IS aerosol was obtained by using a piezoelectric system (Touch Spray)
16 especially designed for the purpose, providing satisfactory results for
17 quantitative bioanalysis after sample extraction. Unfortunately, the Touch Spray
18 device is not available at our lab, and the application of the IS over the filter
19 paper card already impregnated with different blood samples and standards
20 with a simple pipette, or by a similar method, could lead to DBS blurring and
21 sample mixing. From the other two application methodologies, option (iii) is the
22 only one that is fully compatible with DBS sample collection. Self evidently,
23 option (ii) is not applicable to direct sampling from finger tip blood droplets using
24 calibrated pipettes, as described in the introduction, but it may be argued that, *a*
25 *priori* and from an analytical point of view, option (ii) would be preferred, as it
26 ensures that the IS is fully incorporated into the sample matrix together with the
27 analyte before deposition on the filter paper. Hence, the performance of both
28 options, (ii) and (iii), was compared in this work. The addition of the IS to the
29 samples, calibration standards and reference materials following these two
30 deposition methodologies is fully described in section 2.2.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The way in which IS normalization was carried out was different depending
4 on which method had been followed for IS deposition. For DBS where the IS
5 was added to the liquid sample before deposition on the filter paper, the $^{195}\text{Pt}^+$
6 signal was integrated in the same way as those recorded for the rest of the
7 analytes. The response value for samples and standards was then obtained by
8 dividing the analytes' integrated signals by the $^{195}\text{Pt}^+$ integrated signal. This
9 methodology, however, cannot be deployed when papers pretreated with the IS
10 are used for DBS deposition. In this case, Pt is distributed along the whole filter
11 paper surface and hence, the integrated $^{195}\text{Pt}^+$ signal varies with the size of the
12 DBS ablated, so that direct normalization of the analytes' signals with the
13 integrated $^{195}\text{Pt}^+$ signal will lead to erroneous results. In order to avoid this
14 potential problem, the average $^{195}\text{Pt}^+$ signal recorded during the integration
15 interval considered for the analytes was used for normalization instead.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33
34 The performance of the two different IS deposition methods considered was
35 next compared following the protocol described above for data treatment. For
36 this purpose, analysis of the Lyphocheck Whole Blood Control Level 2
37 reference material was carried out using the two different IS deposition
38 strategies. This material was selected as it exhibits comfortable concentration
39 levels for all of the analytes. As seen for Pb in **Figure 5**, satisfactory calibration
40 curves were obtained with both approaches for all of the analytes, showing
41 good linearities ($R^2 > 0.99$) in the concentration ranges monitored (spiked
42 concentrations: 1-100 $\mu\text{g L}^{-1}$ for Cd and Co; 1-500 $\mu\text{g L}^{-1}$ for Pb; 1-2000 $\mu\text{g L}^{-1}$
43 for Cu). Please notice that the slopes of both calibration curves should not be
44 directly compared as the amount of Pt that is incorporated into the filter paper
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 using options (ii) and (iii) is not necessarily the same, although it should remain
4
5 constant for every particular option.
6
7

8 The results obtained after analysis of the reference material, on the other
9
10 hand, are gathered in **Table 3**. As seen from this table, similar results, within
11
12 experimental error, were obtained for all of the analytes using both IS
13
14 deposition methodologies. Moreover, results are in good agreement with the
15
16 reference values (obtained from the certificate of analysis, when available, or
17
18 from analysis of the blood samples by PN-ICP-MS or HR CS GFAAS, as
19
20 described in section 2.2), which demonstrates the validity of the analytical
21
22 protocol developed. RSD values are typically below 10%, except for Co
23
24 (approx. 12%), probably owing to the lower content of this element. Therefore,
25
26 and considering that use of paper discs that were previously pretreated with the
27
28 IS is the only methodology fully compatible with unsupervised sample collection
29
30 schemes, such method of IS addition was chosen for further experiments.
31
32
33
34
35

36 *3.1.4. Analysis of real samples and reference materials. Results and figures of* 37 38 *merit.* 39

40
41 Further validation of the LA-SF-ICP-MS method developed was carried out
42
43 by analyzing a set of 3 real samples and 3 additional reference materials. The
44
45 samples and those reference materials for which some reference values were
46
47 not available from the certificate of analysis were also analyzed by means of
48
49 either PN-ICP-MS (Co, Cd) or HR CS GFAAS (Cu, Pb), following the
50
51 experimental procedures described in section 2.2. Results for those analyses
52
53 are gathered in **Table 4**. As can be seen, the results obtained by means of LA-
54
55 SF-ICP-MS are satisfactory both in terms of accuracy (the small differences
56
57 found when compared with the reference values are always within the
58
59
60

1
2
3 uncertainty of the methods) and reproducibility. RSD values range between 3
4
5 and 9% in the majority of cases (77% of analyses), which seems fit-for-purpose
6
7
8 in a clinical context.
9

10 As for limits of detection (LOD), these were estimated using the signals
11
12 obtained for 5 calibration standards and also monitoring 5 blank filters (only
13
14 milli-q water was deposited onto them). LODs were calculated as 3 times the
15
16 standard deviation of the blank filter signals divided by sensitivity obtained for
17
18 each of the calibration standards. The final value was obtained as the average
19
20 of these 5 individual values and is also displayed in **Table 4** for each of the
21
22 target analytes. The higher values obtained for Co and Cu are probably related
23
24 to the existence of spectral interferences in the ICP-MS not resolved in the low
25
26 resolution mode of analysis deployed ($^{38}\text{Ar}^{23}\text{Na}^+$ and $^{43}\text{Ca}^{16}\text{O}^+$ for $^{59}\text{Co}^+$ and
27
28 $^{40}\text{Ar}^{25}\text{Mg}^+$ for $^{65}\text{Cu}^+$, respectively). Although further experiments would be
29
30 needed, it seems clear that some room for improvement exists in this regard if
31
32 medium resolution is deployed for determination of these two analytes. In this
33
34 work, however, it was preferred to work in the low resolution mode, thus
35
36 ensuring a higher sensitivity, as the LODs achieved already suffice for the vast
37
38 majority of the applications intended. Furthermore, and as shown in **Table 4**,
39
40 very low detection limits were obtained for Cd and Pb. This is not surprising
41
42 considering the extremely high sensitivity that can be achieved with the
43
44 experimental setup deployed, especially the LA unit that is able to ablate a very
45
46 high amount of sample per second. It is worth to indicate at this point that all
47
48 results were obtained with the split-flow experimental setup described in section
49
50 2.4, i.e., by only directing 20% of the LA ablated aerosol into the SF-ICP-MS
51
52 instrument. Although one might consider that, by directing the full amount of
53
54
55
56
57
58
59
60

1
2
3 ablated aerosol into the SF-ICP-MS instrument LODs could be somewhat
4 improved, it is our belief that this would probably lead to increased matrix
5 effects due to the high amount of blood and, especially, paper matrix introduced
6 into the ICP-MS per second, as observed for Cu isotopic analysis in the MC-
7 ICP-MS instrument (see Section 3.2 for more details). As a result, and even if
8 some additional experiments would be needed to exactly determine how much
9 sample matrix can be efficiently dealt with by the ICP-MS, we believe that the
10 LODs provided can be considered as a realistic estimation of what can be
11 achieved with this method of analysis. As previously indicated, only some
12 improvements coming from the use of higher resolution modes for interfered
13 elements could be expected.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **3.2. Simultaneous Cu isotopic analysis by means of split-flow LA-MC-ICP-** 30 **MS** 31 32

33
34 As briefly discussed in the introduction, our recent experience in the field of
35 isotopic analysis of biological samples has demonstrated the potential interest
36 of such isotopic information, combined with quantitative information for the
37 same elements, for diagnosis of metal-related diseases such as Wilson's
38 disease and Cu isotopes.^{33,34} Based on these results, determination of Cu
39 isotope ratios with high precision in the same DBS specimen used for
40 quantitative analysis by split-flow coupling of the LA system to a MC-ICP-MS
41 was attempted in this work, as a mean to provide an analytical method capable
42 of maximizing the information extracted from a single blood spot that might be,
43 for instance, archived in biobanks.
44
45
46
47
48
49
50
51
52
53
54
55
56

57 Unfortunately, the challenges related to this task are noteworthy. To start
58 with, previous results obtained for Cu isotopic determination in serum samples³³
59
60

1
2
3 showed that, for discriminating patients with a certain medical condition related
4 to Cu metabolism from healthy individuals, the method of analysis deployed
5 must provide uncertainty budgets below about 0.5 delta units (2s), or different
6 populations may overlap. For achieving this goal, serum samples were acid-
7 digested in the cited work and Cu was separated from the sample matrix by ion-
8 exchange chromatography, which permitted to virtually eliminate Na from the
9 measuring solutions. In fact, Na is found at high concentrations in serum and
10 blood samples and causes significant interference problems in the ICP-MS that
11 affect both precision and accuracy for Cu isotope ratio determinations. In
12 particular, Na is at the origin of the $^{40}\text{Ar}^{23}\text{Na}^+$ interference on the $^{63}\text{Cu}^+$ signal.
13
14 Considering that Na concentration in serum or blood of healthy patients is about
15 2000 times higher than that of Cu (even higher for Wilson's disease patients),
16 the significance of this interference is very remarkable for this kind of analyses,
17 where extremely good precision and accuracy values are needed.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 When LA is used for sampling dried matrix spots for which minimal sample
37 pre-treatment is aimed at, chemical analyte isolation from the sample matrix
38 before analysis is not feasible and other ways to circumvent the problem of the
39 $^{40}\text{Ar}^{23}\text{Na}^+$ overlap must be found. For this purpose, a method frequently used in
40 the past when instruments fitted with reaction or collision cells were not
41 available yet was first tested in this work. Weakly bonded polyatomic
42 interferences such as $^{40}\text{Ar}^{23}\text{Na}^+$ are believed to be formed by condensation
43 reactions in the interface region of the ICP-MS,⁴⁶ and the use of mixed-gas
44 plasmas (obtained by addition of molecular and inert gases to the coolant,
45 nebulizer or auxiliary Ar gas flows) has been found to reduce the extension in
46 which these condensation reactions occur without affecting analyte sensitivity to
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 a large extent.⁴⁷ In this particular case, N₂ (g) was added in the torch injector of
4 the ICP-MS, a solution that had proved successful in the past for reducing the
5
6
7
8 ⁴⁰Ar²³Na⁺ interference on ⁶³Cu⁺ for seawater analysis.⁴⁸ Moreover, addition of
9
10 N₂ could also help to alleviate other matrix effects that might be present from
11
12 the heavy sample matrix tackled in this work, through provision of more robust
13
14
15 plasma conditions.⁴⁹

16
17 This possibility was first tested with aqueous solutions, without any laser
18
19 coupling. A two-inlet torch was used to introduce the Ar flow needed for
20
21 nebulizing the aqueous solutions (first port), while N₂ was added through the
22
23 second port into the MC-ICP-MS torch, together with He to mimic the conditions
24
25 used for LA analysis. In particular, three different solutions were prepared for
26
27 exploring the effect of N₂ addition in the measured Cu ratios (i) 200 µg L⁻¹ Cu;
28
29 (ii) 400 mg L⁻¹ Na and (iii) 200 µg L⁻¹ Cu + 400 mg L⁻¹ Na, the latter solution
30
31 showing similar concentration ratios for Cu and Na than those observed in real
32
33 blood samples. These solutions were measured in the MC-ICP-MS at different
34
35 N₂ flow rates added to the main He and Ar flows, which were also finely
36
37 optimized for each experiment together with the ion optics to avoid reflected
38
39 power in the instrument to increase too much. Results for these experiments
40
41 are summarized in **Figure 6**.

42
43
44
45
46
47
48 As seen from **Figure 6A**, addition of N₂ to the ICP-MS results in a clear
49
50 reduction of ⁴⁰Ar²³Na⁺ interference on ⁶³Cu⁺, as shown by the increasing ratio
51
52 obtained for signals monitored at m/z=63 in solution (i), containing only Cu, vs.
53
54 solution (ii), containing only Na, when increasing amounts of N₂ were added to
55
56 the system. Unfortunately and as also shown in **Figure 6A**, this is accompanied
57
58 by a significant reduction of analyte sensitivity, reaching a factor of 2 for a flow
59
60

1
2
3 of N₂ of 20 mL min⁻¹. On the other hand, the effect of the N₂ flow added on the
4
5 uncorrected 65/63 isotope ratios is displayed in **Figure 6B**. As seen from this
6
7 figure, 65/63 ratios obtained for solution (iii), containing both Cu and Na, are
8
9 biased low when no N₂ is added to the system due to the formation of ⁴⁰Ar²³Na⁺
10
11 polyatomic species. Even though addition of N₂ significantly improves the 65/63
12
13 ratio obtained for this solution, the results never match those obtained for
14
15 solution (i), containing only Cu, indicating that the interference is only partially
16
17 resolved by using this methodological approach. As a result, and considering
18
19 also the reduction in sensitivity introduced by the addition of N₂ to the system,
20
21 this working methodology was disregarded for further experiments with DBS
22
23 specimens.
24
25
26
27
28

29
30 Being the previous methodology unsuccessful for completely eliminating the
31
32 influence of the ⁴⁰Ar²³Na⁺ interference on the ⁶³Cu⁺ signal, the same approach
33
34 that had provided good results for the analysis of DUS in ref. 34, i.e. working at
35
36 pseudo high resolution mode and measuring the signals at the left side of the
37
38 peak, was used for the rest of the experiments. Although this working
39
40 methodology permitted to circumvent the interference problem for urine
41
42 samples in the cited work, this effect was achieved at the cost of reducing the
43
44 analyte sensitivity by a factor of 10, which ultimately resulted in a considerable
45
46 loss of precision, and this was the reason why this methodological approach
47
48 was not considered from the beginning.
49
50
51

52
53 In addition, the first experiences with the DBS samples and the LA system
54
55 showed that important matrix effects appear in the MC-ICP-MS instrument
56
57 when these specimens were analyzed using the ablation conditions described
58
59 in section 2.3, selected for achieving adequate sensitivity and reasonable
60

1
2
3 analysis time. In particular, the high amount of sample ablated per second and
4
5 the fact that 80% of the ablated aerosol was directed to the MC-ICP-MS,
6
7 caused significant signal suppression in this instrument (directly observed in the
8
9 $^{62}\text{Ni}^+$ signal used for mass bias correction) and lead to torch injector clogging
10
11 after just two or three DBS ablations. To address the problem of clogging, a
12
13 glass fiber filter (see section 2.3. for details) had to be placed just before the
14
15 entrance of the ablated aerosol to the instrument torch (see **Figure 2**), which
16
17 permitted to work without severe sensitivity fluctuations in sessions of more
18
19 than 8 h. On the other hand, and as for the signal suppression observed for
20
21 $^{62}\text{Ni}^+$ in the MC-ICP-MS, ablation of a blank filter permitted to conclude that
22
23 most suppression effects came from the filter paper. This fact is advantageous
24
25 as a similar response in the ICP-MS can be expected for all the DBS samples
26
27 then, despite the possible matrix differences found in the original blood
28
29 samples.
30
31
32
33
34
35

36 A specific study for determining the best precision achievable in laboratory
37
38 conditions by means of this technique was carried out next. For this purpose, a
39
40 set of 5 different DBS specimens from a healthy volunteer with a Cu content of
41
42 about 1 mg L^{-1} was analyzed. The first issue taken into consideration was the
43
44 way of treating the data for correcting 65/63 isotope ratios for mass bias, and
45
46 two different approaches were also tested in this occasion: linear regression
47
48 slope (LRS) and point-by-point methodology.³⁴ In the LRS method, first
49
50 proposed by Fietzke,^{42,43} the raw $^{65}\text{Cu}/^{63}\text{Cu}$ ratio is estimated as the linear
51
52 regression slope of the graphical representation of ^{65}Cu vs. ^{63}Cu signals, which
53
54 is later corrected for mass bias applying Russell's exponential law⁴¹ and the
55
56 signal obtained for the Ni solution simultaneously nebulized and admixed with
57
58
59
60

1
2
3 the ablated aerosol. Conversely, in the point-by-point strategy the 65/63 ratio for
4 every individual measurement (1 value every 5 seconds) is calculated using the
5 signal intensities (blank-corrected) for ^{65}Cu and ^{63}Cu , and those ratios are
6 averaged at the end for the complete transient signal. More details on these
7 correction strategies can be found elsewhere.^{34,43,50} Results for this experiment
8 showed that, as was the case for the analysis of DUS,³⁴ the linear regression
9 slope (LRS) method provides much better precision for the transient signals
10 obtained than the traditional way to process data based on the use a point-by-
11 point methodology. The results obtained with the LRS method are displayed in
12 **Table 5**. As can be seen, RSD values on the corrected ratios of about 800-1500
13 ppm (internal precision) for $^{63}\text{Cu}^+$ signal intensities of approx. 100-200 mV
14 corresponding to Cu contents of about 1 mg L^{-1} are obtained, while the point-by-
15 point methodology provided RSD values up to 4 times worse for the same
16 samples.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The delta values obtained for these specimens, using the Seronorm blood material as reference, are also shown in **Table 5**. As can be noticed, the variation found for every specimen is relatively large (from 1.6 to -2.2 ‰), but the overall delta is very close to zero, as could be expected, because there is *a priori* no reason to find differences in the Cu ratios for a healthy patient and a reference material that typically exhibits the “natural” Cu composition. This delta variation of almost 4 ‰ are obtained in the best analytical situation, if compared to the DBS from patients suffering from different medical conditions affecting Cu metabolism, for which much lower Cu contents can be expected. Nevertheless, these values are comparable to those obtained for analysis of DUS,³⁴ indicating that the use of the split-flow methodology does not introduce

1
2
3 additional sources of uncertainty to the method. While these values may still not
4
5 be good enough to differentiate patients suffering from different diseases
6
7 affecting Cu metabolism from healthy individuals,³³ it seems clear that, in spite
8
9 of the challenge that coupling the three instruments used in this work might
10
11 represent, the method proposed for simultaneous isotopic and quantitative
12
13 analysis of DBS samples is promising and can become a reality if the new MC-
14
15 ICP-MS instrumentation available in the market providing better resolution
16
17 values at a lower sensitivity cost is deployed for analysis.⁵¹

22 **4. Conclusions**

23
24 In this work it has been shown that simultaneous quantitative and isotopic
25
26 information can be obtained after the direct analysis of DBS specimens by split-
27
28 flow LA simultaneously coupled to a MC-ICP-MS and a SF-ICP-MS instrument,
29
30 without degrading the analytical performance of each of the hyphenated
31
32 techniques, which could be a very interesting alternative for maximizing the
33
34 information that can be drawn from a single DBS specimen that might be, e.g.,
35
36 archived in a biobank or difficult to obtain again.

37
38 The selection of an ablation strategy implying the complete sampling of each
39
40 DBS specimen has permitted to achieve for the first time similar analytical
41
42 responses for DBS obtained from real and reference samples by means of LA-
43
44 ICP-MS. In this way, calibration is simplified and can rely upon construction of
45
46 regression curves based on in-house matrix-matched standards (prepared out
47
48 of spiked pooled blood samples from healthy volunteers or from reference
49
50 materials), leading to satisfactory results in terms of precision, accuracy and
51
52 LOD for analysis of real blood samples in the form of DBS.

59 **Acknowledgements**

60

This work has been funded by the Spanish Ministry of Economy and Competitiveness (project CTQ2012-33494), the Aragón Government (Fondo Social Europeo), the Région Aquitaine and Feder.

References

1. R. Guthrie and A. Susi, *Pediatrics*, 1963, **32**, 338-343.
2. P.A. Demirev, *Anal. Chem.*, 2013, **85**, 779-789.
3. J.J. Pitt, *Clin. Biochem. Rev.*, 2010, **31**, 57-68.
4. P.M. Edelbroek, J. van der Heijden and L.M.L. Stolk, *Ther. Drug Monit.*, 2009, **31**, 327-336.
5. P. Beaudette and K.P. Bateman, *J. Chromatogr. B*, 2004, **809**, 153-158.
6. C.P. Stove, A.S.M.E. Ingels, P.M.M. De Kesel and W.E. Lambert, *Crit. Rev. Toxicol.*, 2012, **42**, 230-243.
7. M. Resano, L. Rello, E. García-Ruiz and M.A. Belarra, *J. Anal. At. Spectrom.*, 2007, **22**, 1250-1259.
8. N. Spooner, *Bioanalysis*, 2010, **2**, 1343-1344.
9. P. Timmerman, S. White, S. Globig, S. Lüdtkke, L. Brunet and J. Smeraglia, *Bioanalysis*, 2011, **3**, 1567-1575.
10. S. Tanna and G. Lawson, *Anal. Methods*, 2011, **3**, 1709-1718.
11. T.W. McDade, S. Williams and J.J. Snodgrass, *Demography*, 2007, **44**, 899-925.
12. J.C. Rockett, G.M. Buck, C.D. Lynch and S.D. Perreault, *Environ. health persp.*, 2004, **112**, 94-104.
13. J.V. Cizdziel, *Anal. Bioanal. Chem.*, 2007, **388**, 603-611.
14. P. Elliott and T.C. Peakman, *Int. J. Epidemiol.*, 2008, **37**, 234-244.
15. P. Abu-Rabie, *Bioanalysis*, 2011, **3**, 1675-1678.
16. UK Newborn Screening Programme Centre, *Guidelines for Newborn Blood Spot Sampling*, UK National Screening Committee, February 2012, ISBN: 978-0-9562374-2-2, available from newbornbloodspot.screening.nhs.uk
17. W.H. Hannon, V.R. De Jesús, M.S. Chavez, B.F. Davin, J. Getchell, M. Green, P.V. Hopkins, K.B. Kelm, B. Noorgaard-Pedersen, C. Padilla, E. Plokhovy, J.V. Mei and B.L. Therrell, *Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard*, 6 edn., Clinical and Laboratory Standards Institute (CLSI) Document NBS-01-A6, West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2013.
18. J.V. Mei, S.D. Zobel, E.M. Hall, V.R. de Jesús, B.W. Adam and W.H. Hannon, *Bioanalysis*, 2010, **2**, 1397-1403.
19. A.J. Wilhelm, J.C.G. den Burger, R.M. Vos, A. Chahbouni and A. Sinjewel, *J. Chromatogr. B*, 2009, **877**, 1595-1598.
20. J. Pisonero, B. Fernández and D. Günther, *J. Anal. At. Spectrom.*, 2009, **24**, 1145-1160.
21. J. Koch and D. Günther, *Appl. Spectrosc.*, 2011, **65**, 155-162.
22. R.E. Russo, X. Mao, J.J. Gonzalez, V. Zorba and J. Yoo, *Anal. Chem.*, 2013, **85**, 6162-6177.
23. I. Konz, B. Fernández, M.L. Fernández, R. Pereiro and A. Sanz-Medel, *Anal. Bioanal. Chem.*, 2012, **403**, 2113-2125.

24. D. Hare, C. Austin and P. Doble, *Analyst*, 2012, **137**, 1527-1537.
25. M.R. Flórez, M. Aramendía, M. Resano, A.C. Lapeña, L. Balcaen and F. Vanhaecke, *J. Anal. At. Spectrom.*, 2013, **28**, 1005-1015.
26. M. Aramendía, L. Rello, F. Vanhaecke and M. Resano, *Anal. Chem.*, 2012, **84**, 8682-8690.
27. W. Nischkauer, F. Vanhaecke, S. Bernacchi, C. Herwig, and A. Limbeck, *Spectrochim Acta B*, 2014, **101**, 123-129.
28. D. Pozebon, G.L. Scheffler, V.L. Dressler and M.A.G. Nunes, *J. Anal. At. Spectrom.*, 2014, in press, doi: 10.1039/C4JA00250D.
29. H.-F. Hsieh, W.-S. Chang, Y.-K. Hsieh and C.-F. Wang, *Talanta*, 2009, **79**, 183-188.
30. H.-F. Hsieh, W.-S. Chang, Y.-K. Hsieh, and C.-F. Wang, *Anal. Chim. Acta*, 2011, **699**, 6-10.
31. A. Sarmiento-González, J.M. Marchante-Gayón, J.M. Tejerina-Lobo, J. Paz-Jiménez and A. Sanz-Medel, *Anal. Bioanal. Chem.*, 2008, **391**, 2583-2589.
32. A. Ala, A.P. Walker, K. Ashkan, J.S. Dooley and M.L. Schilsky, *The Lancet*, 2007, **369**, 397-408.
33. M. Aramendía, L. Rello, M. Resano and F. Vanhaecke, *J. Anal. At. Spectrom.*, 2013, **28**, 675-681.
34. M. Resano, M. Aramendía, L. Rello, M.L. Calvo, S. Bérail and C. Pécheyran, *J. Anal. At. Spectrom.*, 2013, **28**, 98-106.
35. J. Mommers, Y. Mengerink, E. Ritzen, J. Weusten, J. van der Heijden and S. van der Wal, *Anal. Chim. Acta*, 2013, **774**, 26-32.
36. E. Ricard, C. Pécheyran, G. Sanabria Ortega, A. Prinzhofer and O.F.X. Donard, *Anal. Bioanal. Chem.*, 2011, **399**, 2153-2165.
37. C. Pécheyran, S. Cany, P. Chabassier, E. Mottay and O.F.X. Donard, *J. Phys. Conf. Ser.*, 2007, **59**, 112-117.
38. H.-L. Yuan, S. Gao, M.-N. Dai, C.-L. Zong, D. Günther, G.H. Fontaine, X.-M. Liu, and C.R. Diwu, *Chem. Geol.*, 2008, **247**, 100-118.
39. G. Ballihaut, L. Tastet, C. Pécheyran, B. Bouyssiere, O. Donard, R. Grimaud and R. Lobinski, *J. Anal. At. Spectrom.*, 2005, **20**, 493-499.
40. G. Ballihaut, F. Claverie, C. Pécheyran, S. Mounicou, R. Grimaud and R. Lobinski, *Anal. Chem.*, 2007, **79**, 6874-6880.
41. F. Vanhaecke, L. Balcaen and D. Malinovsky, *J. Anal. At. Spectrom.*, 2009, **24**, 863-886.
42. J. Fietzke, M. Frische, T.H. Hansteen and A. Eisenhauer, *J. Anal. At. Spectrom.*, 2008, **23**, 769-772.
43. J. Fietzke, V. Liebetrau, D. Günther, K. Gürs, K. Hametner, K. Zumholz, T.H. Hansteen and A. Eisenhauer, *J. Anal. At. Spectrom.*, 2008, **23**, 955-961.
44. http://www.hawksley.co.uk/blood_analysis/02i_pipettes/index.shtml, last accessed November 2014.
45. P. Abu-Rabie, P. Denniff, N. Spooner, J. Brynjolfssen, P. Galluzzo and G. Sanders, *Anal. Chem.*, 2011, **83**, 8779-8786.
46. H. Niu and R.S. Houk, *Spectrochim. Acta Part B*, 1996, **51**, 779-815.
47. B.S. Sheppard and J.A. Caruso, *J. Anal. At. Spectrom.*, 1994, **9**, 145-149.
48. M.J. Bloxham, P.J. Worsfold and S.J. Hill, *Anal. Proc.*, 1994, **31**, 95-97.
49. C. Agatemor and D. Beauchemin, *Anal. Chim. Acta*, 2011, **706**, 66-83.
50. V.N. Epov, S. Berail, M. Jimenez-Moreno, V. Perrot, C. Pecheyran, D.

- 1
2
3 Amouroux and O.F.X. Donard, *Anal. Chem.*, 2010, **82**, 5652-5662.
4 51. L. Yang, *Mass Spectrom. Rev.*, 2009, **28**, 990-1011.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Instrumental operating conditions used for split-flow simultaneous multielement and Cu isotopic analysis of the blood samples in the form of DBS

Laser ablation conditions															
Laser Ablation System	Lambda 3 fitted with a HP2 fs Laser source														
Wavelength	1030 nm														
Pulse duration	400 fs														
Repetition rate	30000 Hz														
Spot diameter (Airy 1/e ²)	21 μm														
Energy / Fluence	135 μJ / 39 J cm ⁻²														
Scan speed (y axis)	10 mm s ⁻¹														
Stage speed (x axis)	30 μm s ⁻¹														
Ablation strategy	Circles (5 or 6 mm Ø), made with 250-285 concentric circumferences														
Transport gas	He, 1 L min ⁻¹														
Element XR SF-ICP-MS															
RF Power	1400 W														
Ar plasma/auxiliary flow rates	15.0/1.0 L min ⁻¹														
Sampling cone and skimmer	Ni														
N ₂ flow for Jet Interface	10 mL min ⁻¹														
% of total He flow split	20%														
Lens voltages	Optimized daily for maximum sensitivity														
Scanning mode	E-scan														
Settling time	Variable depending on the mass jump 1-100 ms														
Dwell time per acquisition point	10 ms														
Acquisition points per peak	100														
Mass window scanned	5%														
Acquisition time per replicate	260 s														
Resolution mode	Low Res (m/Δm~400)														
Nuclides monitored	⁵⁹ Co ⁺ , ⁶⁵ Cu ⁺ , ¹¹¹ Cd ⁺ , ¹⁹⁵ Pt ⁺ , ²⁰⁸ Pb ⁺														
Nu MC-ICP-MS															
RF Power	1300 W														
Instrument resolution	Pseudo-High Resolution ~ 5700 (Edge resolved power)														
Source slit width	0.05 mm														
Alpha 1 slit	80 mA														
Alpha 2 slit	90 mA														
Integration time	5 s														
Plasma gas flow rate	13.0 L min ⁻¹														
Auxiliary gas flow rate	0.80 L min ⁻¹														
Nebulizer pressure	28.8 psi														
% of total He flow split	80%														
Faraday cup configuration															
Collector	H7	H6	H5	H4	H3	H2	H1	Ax	L1	L2	IC0	L3	IC1	IC2	L4
m/z	65					63			62			61			

Table 2. Average ratio (n=3) between signals obtained for 5 μL and 15 μL DBS specimens of a real blood sample by means of LA-SF-ICP-MS and % deviation from the theoretical value of three, both without and with the use of Pt as internal standard. The internal standard was added to the filter paper prior to the deposition of the sample.

	Internal Standard	Cd	Co	Cu	Pb
Ratio signal 5 μL / 15 μL	No IS	3.4	3.4	2.6	2.5
% Deviation		12.3	14.7	-14.0	-15.4
Ratio signal 5 μL / 15 μL	Pt as IS	2.9	3.2	2.8	2.8
% Deviation		-2.1	6.3	-8.3	-7.4

Table 3. Results for the analysis of Lyphocheck Whole Blood Control Level 2 with the two different methodologies tested for IS deposition. Uncertainty is expressed as 2s (n=5). All values are expressed as $\mu\text{g L}^{-1}$.

Analyte	Pt added to the liquid sample	Pt added to the filter paper	Reference value
Cd	22.3 ± 1.5	21.6 ± 1.4	$21.0 \pm 4.2^{\text{a}}$
Co	3.8 ± 0.9	4.2 ± 0.8	$3.8 \pm 0.4^{\text{b}}$
Cu	584 ± 81	511 ± 88	$526 \pm 24^{\text{c}}$
Pb	286 ± 22	301 ± 24	$297 \pm 59^{\text{a}}$

^a Reference values available from certificate of analysis.

^b Reference value obtained by means of PN-ICP-MS.

^c Reference value obtained by means of HR CS GFAAS.

Table 4. Results and LOD for three reference materials (Seronorm, Clincheck Level II and Lipocheck Level I) and three real samples (M1, M2, M4) analyzed by means of LA-SF-ICP-MS following the experimental methodology described in section 2.4. All values are expressed as $\mu\text{g L}^{-1}$. Uncertainty values are expressed as 2s.

		Seronorm	Clincheck Level II	Lipocheck Level I	Real sample M1	Real sample M2	Real sample M4
	Ref. value	6.0 ± 0.4^a	3.14 ± 0.63^a	11.6 ± 2.3^a	0.15 ± 0.02^b	0.17 ± 0.01^b	0.21 ± 0.03^b
Cd	LA-SF-ICP-MS	5.6 ± 0.2	2.75 ± 0.24	12.0 ± 1.4	0.10 ± 0.03	0.17 ± 0.02	0.18 ± 0.02
	LOD				0.043		
	Ref. value	6.1 ± 0.4^a	4.17 ± 0.83^a	2.2 ± 0.8^b	0.48 ± 0.05^b	1.58 ± 0.19^b	0.76 ± 0.07^b
Co	LA-SF-ICP-MS	6.8 ± 0.8	4.43 ± 0.81	2.0 ± 0.7	<LOQ ^d	1.70 ± 0.24	<LOQ ^d
	LOD				0.42		
	Ref. value	666 ± 58^a	805 ± 70^c	586 ± 66^c	818 ± 46^c	958 ± 75^c	858 ± 81^c
Cu	LA-SF-ICP-MS	646 ± 110	857 ± 136	594 ± 102	892 ± 136	948 ± 163	729 ± 126
	LOD				0.54		
	Ref. value	393 ± 21^a	237 ± 47^a	117 ± 23^a	22 ± 1.1^c	28 ± 2.1^c	58 ± 4.1^c
Pb	LA-SF-ICP-MS	381 ± 26	259 ± 26	144 ± 23	24 ± 2.7	27 ± 3.5	55 ± 5.3
	LOD				0.040		

^a Reference values available from certificate of analysis.

^b Reference value obtained by means of PN-ICP-MS.

^c Reference value obtained by means of HR CS GFAAS.

^d Defined as ten times the standard deviation of the blank filter signals divided by the sensitivity.

Table 5. Cu isotopic composition of 5 different DBS specimens from a healthy volunteer with a Cu content of about 1 mg L⁻¹, presented as $\delta^{65}\text{Cu}$, the relative deviation (in per mil) *versus* a DBS specimen prepared with a reference sample (Seronorm). The RSD values indicate the internal precision of every measurement, and the overall RSD reflects the variation between the 5 specimens. The LRS method was used to correct for mass bias.

	$\delta^{65}\text{Cu}$ (‰)	RSD (ppm)
DBS 1	1.57	1160
DBS 2	1.33	1330
DBS 3	-2.17	1560
DBS 4	0.21	800
DBS 5	-0.92	770
Overall	0.03	1570

Figure captions

Figure 1. Filter paper discs with 5 μL dried blood spots (DBS) from different CRMs (highlighted in the figure) and real samples (spiked and unspiked). (A) Before ablation. The different dispersion properties of the CRMs and the real samples can be clearly appreciated; (B) After ablation. Each ablated area completely covers the DBS plus a variable part of blank paper depending on the DBS size.

Figure 2. Experimental setup for split-flow simultaneous elemental and isotopic analysis of the DBS samples by means of LA-ICP-MS, using two different types of ICP-MS devices (SF-ICP-MS and MC-ICP-MS).

Figure 3. Schematic representation of the ablation protocol used for analysis of the 5 μL dried blood spots. 5-6 mm diameter craters (depending on the DBS size) were constructed by ablating 250-285 concentric circumferences from the inside to the outside of the DBS. All circles were ablated at the same speed.


Figure 4. Approximated radial distribution of Pb in 5 μL DBS obtained from: A) a real sample B) Lipocheck Level I reference sample C) Seronorm Level II reference sample. Each bar represents the integrated $^{208}\text{Pb}^+$ signal, normalized for a concentration of $1 \mu\text{g L}^{-1}$, for the ablated corona with internal and external radius indicated in the x-axis in the figure.

Figure 5. Calibration curves for Pb obtained with matrix-matched standards (5 μL DBS specimens) prepared from a real sample spiked with known Pb amounts, with either Pt added to the liquid sample (blue diamonds) or Pt previously added to the filter paper (red squares).

Figure 6. Experiments for reduction of the $^{40}\text{Ar}^{23}\text{Na}^+$ interference on the $^{63}\text{Cu}^+$ signal through addition of N_2 to the plasma in the Nu MC-ICP-MS instrument.

1
2
3 (A) Left y-axis: ratio for the signals monitored at $m/z=63$ obtained for solution (i),
4 containing $200 \mu\text{g L}^{-1}$ Cu, vs. solution (ii), containing 400mg L^{-1} Na; Right y-
5 axis: signal intensity obtained at $m/z=63$ for solution (i). (B) Uncorrected 65/63
6 ratios obtained for solution (i) and for solution (iii), which contains $200 \mu\text{g L}^{-1}$ Cu
7 + 400mg L^{-1} Na.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2





Figure 3



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4




Figure 5




Figure 6

